Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Copenhagen | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Antagonizing GIP effects during hyperglycaemia in healthy subjects and measurements of insulin secretion.
Aim: To evaluate the GIP receptor antagonizing effect of peptide-based competitive GIP receptor antagonist GIP-A (vs. saline (placebo)) in 10 healthy subjects during 1 hour hyperglycaemic clamps with and without concomitant iv infusion of GIP[1-42]. The intention is to establish GIP-A as a tool to eliminate glucose-dependent insulinotropic GIP signalling.
The study consists of four experimental days (A-D) with assessment of beta cell function during 12 mM-hyperglycaemic clamps with concomitant infusions of A) GIP[1-42], B) GIP-A, C) GIP[1-42] + GIP-A, or D) saline (placebo).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Infusion of saline |
|
| GIP(1-42) | Active Comparator | Infusion of agonist, GIP(1-42) |
|
| GIP-A | Experimental | Infusion of GIP-A alone |
|
| GIP-A + GIP(1-42) | Experimental | Infusion of GIP-A and GIP(1-42) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GIP-A | Drug | GIP receptor antagonist |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Insulin levels | Serum-insulin AUC (area under the curve for hyperglycemic clamp period) | 65 minutes |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Filip K Knop, MD, PhD | UHGentofte, Center for Diabetes Research | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center for Diabetes Research | Copenhagen | Gentofte | 2900 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28948296 | Derived | Gasbjerg LS, Christensen MB, Hartmann B, Lanng AR, Sparre-Ulrich AH, Gabe MBN, Dela F, Vilsboll T, Holst JJ, Rosenkilde MM, Knop FK. GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia. 2018 Feb;61(2):413-423. doi: 10.1007/s00125-017-4447-4. Epub 2017 Sep 25. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C101760 | gastric inhibitory polypeptide (1-42) |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| GIP(1-42) |
| Drug |
GIP receptor agonist |
|
| Saline | Other | Placebo |
|
| D017670 |
| Sodium Compounds |